About Netia Medical Technologies

About company

Netia will license the use of its single strand RNAi drug development platform to pharmaceutical companies; 6 patent filings undergird the technology. Netia's platform generates better drugs that are much less expensive. The cost to take a conventional drug to market averages $2.6B while a comparable drug based on Netia's platform costs less than half as much, and reduces the amount of time required to get to market by 3 years. Further, drugs based on the Netia platform can penetrate hundreds of therapeutic targets that are untouchable by conventional drugs.